New Triple-Threat treatment tested for tough kidney cancers
NCT ID NCT05501054
Summary
This study is testing a new combination of three drugs (ciforadenant, ipilimumab, and nivolumab) to see if it can help control advanced kidney cancer that has spread. It will involve about 50 adults who have not yet received any treatment for their advanced cancer. The main goals are to check if the drug combination is safe and to see how well it shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.